GoAI
Get started
Pliant Therapeutics, Inc. logo

Pliant Therapeutics, Inc.

PLRX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.155

+$0.035 · +3.12%

Aug 21, 4:00 PM ET

PLRX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

32

Expensive

Momentum

40

Weakening

Sentiment

45

Mixed

Risk resilience

43

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Bernard Coulie
Listed since
Jun 3, 2020
Employees
49

Market position

Day range

Current $1.155

52-week range

Current $1.155

Open
$1.15
Previous close
$1.12
Volume
504.69K
0.96× average
Average volume
527.85K
Average daily volume
Market cap
71.52M USD
Beta
1.27
Market reference 1
50-day average
$1.1101
+4.04% above average
200-day average
$1.251
-7.67% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
58.53M USD
EV / EBITDA
-0.4×
Earnings yield
-199.48%
Free cash flow yield
-171.92%

Profitability & efficiency

Return on equity
-82.42%
Return on assets
-66.31%
Return on invested capital
-71.36%

Financial health

Current ratio
12×
Altman Z-score
-6.28
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1275%-3426%-8128%-12830%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Operating margin, FY2021: -1288.10%Operating margin, FY2022: -1313.37%Operating margin, FY2023: -11654.75%Net margin, FY2021: -1284.51%Net margin, FY2022: -1273.32%Net margin, FY2023: -10211.14%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Operating margin FY2021 -1288.10%. Operating margin FY2022 -1313.37%. Operating margin FY2023 -11654.75%. Net margin FY2021 -1284.51%. Net margin FY2022 -1273.32%. Net margin FY2023 -10211.14%.

Income trends

Revenue

1.58M USD-83.69%

Operating income

−150.07M USD+34.28%

Net income

−149.34M USD+28.99%
Income trends across reported periods33.49M USD−61.73M USD−156.95M USD−252.17M USDRevenue, FY2021: 7.57M USDRevenue, FY2022: 9.69M USDRevenue, FY2023: 1.58M USDOperating income, FY2021: −97.54M USDOperating income, FY2022: −127.2M USDOperating income, FY2023: −184.15M USDOperating income, FY2024: −228.37M USDOperating income, FY2025: −150.07M USDNet income, FY2021: −97.26M USDNet income, FY2022: −123.32M USDNet income, FY2023: −161.34M USDNet income, FY2024: −210.3M USDNet income, FY2025: −149.34M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 7.57M USD. Revenue FY2022 9.69M USD. Revenue FY2023 1.58M USD. Operating income FY2021 −97.54M USD. Operating income FY2022 −127.2M USD. Operating income FY2023 −184.15M USD. Operating income FY2024 −228.37M USD. Operating income FY2025 −150.07M USD. Net income FY2021 −97.26M USD. Net income FY2022 −123.32M USD. Net income FY2023 −161.34M USD. Net income FY2024 −210.3M USD. Net income FY2025 −149.34M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue——1.58M USD9.69M USD7.57M USD
Cost of goods sold1.7M USD————
Gross profit−1.7M USD—1.58M USD9.69M USD7.57M USD
Research and development109.16M USD169.31M USD127.8M USD96.94M USD77.55M USD
Selling, general, and administrative47.22M USD59.06M USD57.93M USD39.95M USD27.56M USD
Operating expenses148.38M USD228.37M USD185.73M USD136.89M USD105.11M USD
Interest income—21.09M USD24.08M USD4.67M USD272K USD
Interest expense2.56M USD3.02M USD1.27M USD791K USD—
Depreciation and amortization1.7M USD2.13M USD1.84M USD3.68M USD1.54M USD
Operating income−150.07M USD−228.37M USD−184.15M USD−127.2M USD−97.54M USD
Net income−149.34M USD−210.3M USD−161.34M USD−123.32M USD−97.26M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+3.09%
11 comparable reports
Latest EPS result
-0.36
Estimate -0.34 · Miss by 5.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.27-0.53-0.79-1.04Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual -0.82, estimate -0.99, surprise +17.17%, Beat. Q2 2025, reported May 8, 2025: actual -0.92, estimate -0.78, surprise -17.95%, Miss. Q3 2025, reported Aug 7, 2025: actual -0.71, estimate -0.62, surprise -14.52%, Miss. Q4 2025, reported Nov 6, 2025: actual -0.43, estimate -0.53, surprise +18.87%, Beat. Q1 2026, reported Mar 11, 2026: actual -0.35, estimate -0.42, surprise +16.67%, Beat. Q2 2026, reported May 11, 2026: actual -0.32, estimate -0.36, surprise +11.11%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.36, estimate -0.342, surprise -5.33%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.37, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.39M3.62M1.84M70.83KQ1 '24BeatQ2 '24EstimateQ3 '24EstimateQ4 '24EstimateQ1 '26Estimate
Q1 2024, reported Feb 27, 2024: actual 4.84M USD, estimate 814.11K USD, surprise +494.51%, Beat. Q2 2024, reported May 6, 2024: actual —, estimate 460K USD, surprise —, Comparison unavailable. Q3 2024, reported Aug 7, 2024: actual —, estimate 490K USD, surprise —, Comparison unavailable. Q4 2024, reported Nov 7, 2024: actual —, estimate 83.33K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 11, 2026: actual —, estimate 5M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$3.00

159.74% upside
Past 12 months12-month forecastHigh $3.00Average $3.00Low $3.00

Rating distribution

16 ratings
Strong buy00%
Buy850%
Hold744%
Sell16%
Strong sell00%

PLRX news

globenewswire.com

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for…

Read source
globenewswire.com

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D.

Read source
globenewswire.com

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.

Appointments bring global oncology drug development experience and deepen Board's operational and regulatory expertise

Read source

PLRX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PLRX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.82M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
640.43K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
234.44K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
161.06K
Weight
0.00%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%
Invesco RAFI US 1500 Small-Mid ETF logoInvesco RAFI US 1500 Small-Mid ETFPRFZ
Market value
116.52K
Weight
0.00%
AUM
2.87B USD
Expense ratio
0.34%
Price / 1D
$55.89+0.87%

Continue in GoAI

Research PLRX

research.disclaimer